New Products: Nasal spray launched to treat nocturia due to nocturnal polyuria

Nasal spray launched to treat nocturia due to nocturnal polyuria

Avadel Pharmaceuticals plc has announced the launch of desmopressin acetate (NOCTIVA), an emulsified microdose nasal spray. Desmopressin is the first and only FDA-approved treatment proven to help adults with nocturia due to nocturnal polyuria, according to Avadel. The treatment’s formulation works in the kidneys to lessen nighttime urine production. The nasal spray is a proprietary emulsified microdose of desmopressin combined with a permeation enhancer that increases the transport of desmopressin across the nasal mucosa. Delivered via a unique spray pattern, NOCTIVA’s formulation substantially increases the bioavailability of the active drug, allowing for microdosing, rapid absorption, and consistency from dose to dose.